Beta Drugs' Q3 FY 2025-26 Quarterly Results
- 15 Feb 2026
Result Summary
- Beta Drugs Ltd reported a - quarter-on-quarter (QoQ) - in its consolidated revenues for the quarter-ended Dec (Q3 FY 2025-26). On a year-on-year (YoY) basis, it witnessed a - of -.
- Its expenses for the quarter were - by - QoQ and - - YoY.
- The net profit - - QoQ and - - YoY.
- The earnings per share (EPS) of Beta Drugs Ltd stood at 8.4 during Q3 FY 2025-26.
Financial Statments for Q3 FY 2025-26
Total Income | 89.58 | 0.00 | 0.00 | - | - |
Total Expenses | 79.10 | 0.00 | 0.00 | - | - |
Profit Before Tax | 10.47 | - | - | NaN% | NaN% |
Tax | 1.95 | 0.00 | 0.00 | - | - |
Profit After Tax | 8.52 | 0.00 | 0.00 | - | - |
Earnings Per Share | 8.40 | 0.00 | 0.00 | - | - |
Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results
Company Overview
Beta Drugs Ltd is primarily engaged in the pharmaceutical industry, focusing on the development, manufacturing, and marketing of a wide range of pharmaceutical products. The company is known for its commitment to delivering high-quality medications across various therapeutic segments. As a player in the pharmaceutical sector, Beta Drugs Ltd operates in a highly regulated environment, ensuring compliance with stringent quality standards. While specific recent major developments are not available in the provided data, the company continues to position itself as a significant entity in the industry, leveraging its expertise for sustainable growth and innovation.
Revenue
During the third quarter of the fiscal year 2026 (Q3FY26), Beta Drugs Ltd reported total income of ₹89.58 crores. This figure represents the revenue generated from the company's operations during this period. As the data for the previous quarter (Q2FY26) and the same quarter of the previous year (Q3FY25) is not provided, comparative analysis in terms of quarter-over-quarter (QoQ) and year-over-year (YoY) growth rates is not available. The total income figure serves as a crucial indicator of the company's operational scale and market presence during Q3FY26.
Profitability
Beta Drugs Ltd achieved a profit before tax of ₹10.47 crores in Q3FY26, reflecting the earnings from its operations before accounting for tax expenses. The tax expense for the quarter amounted to ₹1.95 crores, resulting in a profit after tax of ₹8.52 crores. These figures provide insight into the company's profitability during the period. The earnings per share (EPS) for Q3FY26 stood at ₹8.40, indicating the portion of profit allocated to each share of common stock. Due to the absence of previous period data, an analysis of profitability trends over time is not feasible. Nonetheless, these metrics underscore the company's ability to generate profit from its core operations in the reported quarter.
Operating Metrics
The provided financial data does not include specific operating metrics such as sales volume, operating margin, or other efficiency ratios. However, the total expenses for Q3FY26 were reported at ₹79.10 crores, which, when subtracted from the total income, resulted in the profit before tax. The available data highlights the company's cost structure and efficiency in managing its expenses relative to its total income. Without comparative data from previous quarters or years, further analysis of operating trends or efficiency improvements is not possible. The focus remains on the reported financial outcomes for the third quarter of the fiscal year 2026.